News Quantified

NTLA – intellia therapeutics, inc. (US:NASDAQ)

Intellia Therapeutics, Inc. (NASDAQ: NTLA) had its price target lowered by analysts at Oppenheimer Holdings Inc. from $70.00 to $60.00. They now have an "outperform" rating on the stock.

11/9

10:11 am

ntla

Medium

Intellia Therapeutics, Inc. (NASDAQ:NTLA) Just Reported Third-Quarter Earnings And Analysts Are Lifting Their Estimates [Yahoo! Finance]

Intellia Therapeutics, Inc. (NASDAQ: NTLA) was upgraded by analysts at StockNews.com to a "sell" rating.

Intellia Therapeutics, Inc. (NASDAQ: NTLA) had its price target lowered by analysts at Barclays PLC from $76.00 to $55.00. They now have an "overweight" rating on the stock.

Intellia Therapeutics Inc (NTLA) Q3 2024 Earnings Call Highlights: Financial Stability and ... [Yahoo! Finance]

Live Event: Join our next subscriber-only event: "The Data Driven Investor"

Register for our next upcoming LIVE training session, which will be hosted on Tuesday April 24th at 08:00 PM EST (New York Time).
Get your questions answered during the Q & A session.
For any support questions, contact our team: support@newsquantified.com

Click Here To Register For The Live Online Workshop

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

52 Week High	{{GetCompanyStockInfo.Week52HighValue}} {{GetCompanyStockInfo.Week52HighDate}}
52 Week Low	{{GetCompanyStockInfo.Week52LowValue}} {{GetCompanyStockInfo.Week52LowDate}}

Today’s Volatility	{{VolatilityStr}}
20 Day Volatility	{{Volatility20Str}}

Open	{{GetCompanyStockInfo.Open}}
Prior Close	{{GetCompanyStockInfo.PriorCloseValue}} {{GetCompanyStockInfo.PriorCloseDate}}